Genetron Holdings (Genetron Holdings) Debt-to-Revenue : 0.29 (As of Jun. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Genetron Holdings Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Genetron Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $16.72 Mil. Genetron Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $7.34 Mil. Genetron Holdings's annualized Revenue for the quarter that ended in Jun. 2022 was $82.30 Mil. Genetron Holdings's annualized Debt-to-Revenue for the quarter that ended in Jun. 2022 was 0.29.

Genetron Holdings Debt-to-Revenue Historical Data

The historical data trend for Genetron Holdings's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetron Holdings Debt-to-Revenue Chart

Genetron Holdings Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Revenue

Get a 7-Day Free Trial

0.21

0.29

0.14

0.24

Genetron Holdings Quarterly Data
	Dec17	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22
Debt-to-Revenue	Get a 7-Day Free Trial													0.13	0.13	0.19	0.29	N/A

Competitive Comparison of Genetron Holdings's Debt-to-Revenue

For the Diagnostics & Research subindustry, Genetron Holdings's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genetron Holdings's Debt-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetron Holdings's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Genetron Holdings's Debt-to-Revenue falls into.

Genetron Holdings Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Genetron Holdings's Debt-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(18.822	+	3.922)	/	93.335
	=	0.24

Genetron Holdings's annualized Debt-to-Revenue for the quarter that ended in Jun. 2022 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(16.719	+	7.343)	/	82.296
	=	0.29

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jun. 2022) Revenue data.

Genetron Holdings Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Genetron Holdings's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetron Holdings (Genetron Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetron Holdings Ltd (NAS:GTH) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 8 Life Science Parkway, 1-2nd Floor, Building 11, Zone 1, Changping District, Beijing, CHN, 102206

Website

https://www.genetronhealth.com

Genetron Holdings Ltd is an oncology company in China. It is specialized in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The company's operating segment includes Diagnosis and monitoring - provision for LDT services; Diagnosis and monitoring - sale of IVD products and Development services. It generates maximum revenue from the Diagnosis and monitoring - provision for LDT services segment.